Neo-NTP-CRT for Locally Advanced ESCC

Locally Advanced Esophageal Squamous Cell Carcinoma Clinical Trial

— Neo-NTP-CRT  

Official title:

Neoadjuvant Nivolumab Plus Paclitaxel/ Cisplatin- Chemo- Radiotherapy (Neo-NTP-CRT) Followed by Esophagectomy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05130684
• Other study ID #: 202005115MIPB
• Status: Recruiting
• Phase: Phase 2
• Start date: February 22, 2021
• Est. completion date: March 1, 2024

Study information

• Verified date: April 2021
• Source: National Taiwan University Hospital
• Contact: Ta-Chen Huang, MD
• Phone: +886223123456
• Email: e360215[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators hypothesize that nivolumab combined with neoadjuvant chemoradiotherapy (CRT) is safe and effective in patients with locally advanced esophageal squamous cell carcinoma (LAESCC).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 43
• Est. completion date: March 1, 2024
• Est. primary completion date: March 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Pathologically proven squamous cell carcinoma of the intrathoracic esophagus.

2. Locally advanced disease, which is defined by the TNM system of the American Joint Committee on Cancer (AJCC) Cancer Staging System (8th edition), fulfilling one of the following criteria as determined by endoscopic ultrasound, computed tomography, bronchoscopy and positron emission tomography:

1. cT3/4a, N0, M0;

2. cT1-3, N1-3, M0.

3. Tumor length longitudinal = 8cm and radial = 5cm.

4. The tumor must not extend more than 2cm into the stomach.

5. No invasion of the tracheobronchial tree or presence of tracheoesophageal fistula.

6. Age = 20 and = 75 years old.

7. Performance status ECOG 0~1.

8. Adequate bone marrow reserves, defined as:

1. white blood cells (WBC) = 4,000/µl or neutrophil count (ANC) = 2,000/µl;

2. platelets = 100,000/µl.

9. Adequate liver function reserves, defined as:

1. hepatic transaminases = 2.5 x upper limit of normal (ULN);

2. serum total bilirubin = 2.0 x upper limit of normal (ULN).

10. Adequate renal function: Creatinine =1.5 x upper normal limit or estimated creatinine clearance = 50 ml/min (estimated by Cockcroft-Gault formulation)

11. Written informed consent.

12. Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

13. Female subjects of childbearing potential must be willing to use an adequate method of contraception as outlined in Section - Contraception, for the course of the study through 120 days after the last dose of study medication.

Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.

14. Male subjects of childbearing potential must agree to use an adequate method of contraception as outlined in Section - Contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy.

Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.

Exclusion Criteria:

1. Adenocarcinoma.

2. Previous thoracic irradiation.

3. Previous systemic chemotherapy

4. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.

5. Synchronously diagnosed squamous cell carcinoma of aerodigestive way, other than esophageal cancer.

6. Prior malignancy, except for the following:

1. adequately treated basal cell or squamous cell skin cancer;

2. in-situ cervical cancer;

3. a "cured" malignancy more than 5 years prior to enrollment.

7. Significant co-morbid disease, which prohibits the conduction of chemotherapy, concurrent chemo- radiotherapy, or radical surgery, such as active systemic infection, symptomatic cardiac or pulmonary disease, or psychiatric disorders.

8. Documented myocardial infarction within the 6 months preceding registration (pretreatment ECG evidence of infarct only will not exclude patients). Patients with a history of significant ventricular arrhythmia requiring medication. Patients with a history of 2nd or 3rd degree heart block.

9. Pre-existing motor or sensory neurotoxicity greater than grade 1.

10. Patients with prior allergic reactions to drug containing Cremophor, such as teniposide or cyclosporine.

11. Weight loss > 15%.

12. Dementia or altered mental status that would prohibit the understanding and completion of informed consent.

13. Estimated life expectancy less than 3 months.

14. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.

15. Has a known history of active TB (Bacillus Tuberculosis)

16. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.

17. Has known history of, or any evidence of active, non-infectious pneumonitis, interstitial lung disease or pulmonary fibrosis.

18. Concurrent diverticulitis or symptomatic gastrointestinal ulcerative disease.

19. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.

20. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).

21. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., anti-HCV reactive and HCV RNA [qualitative] are detected).

22. Patients with a negative HBs antigen test but a positive test result for either HBs antibody or HBc antibody with a detectable level of HBV-DNA.

23. Has received a live vaccine within 30 days of planned start of study therapy. Note:

Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.

24. Has received organ transplantation.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Esophageal Squamous Cell Carcinoma
• Locally Advanced Esophageal Squamous Cell Carcinoma

Intervention

Drug:
• Nivolumab
adding nivolumab to conventional neoadjuvant CRT

Locations

Country	Name	City	State
Taiwan	National Taiwan University Hospital	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
National Taiwan University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	change in treatment related death	no increase of treatment-related death within 30 days after esophagectomy	30 days
Primary	rate of completion of protocol treatment	successful completion of preoperative therapy and processing to surgery without any extended treatment-related delay, which is defined as > 19 weeks after the first dose of nivolumab (d-14) in neo-NTP-CRT (19 weeks include 15 weeks of protocol treatment plus 4 weeks of flexibility.).	5 months